Samsung Bioepis cancer drug under review by FDASamsung Bioepis said Wednesday that the U.S. Food and Drug Administration has begun reviewing its license application for a cancer-fighting biosimilar called SB3.
A biosimilar is a drug with active properties similar to a previously licensed one. SB3 references Herceptin, a breast cancer drug from Swiss pharmaceutical company Roche.
According to Samsung Bioepis, SB3 is the company’s first oncological biosimilar submitted for regulatory review in the United States.
By Kim Jee-hee
More in Industry
EuCorVac-19 vaccine gets greenlight for trials
Tesla model to lose government subsidies
Jailed Lee vows to support Samsung compliance committee
Samsung Display will make display with higher refresh rate
Clean start to the Lunar New Year